Research Article| Volume 20, SUPPLEMENT 3, C26-C31, 1998

Realizing the promise of the US food and drug administration modernization act

  • RichardL. Wolgemuth
    Address correspondence to: Richard L. Wolgemuth, PhD, Vice President, US Regulatory Affairs, Glaxo Wellcome Inc., 5 Moore Drive, Research Triangle Park, NC 27709.
    Glaxo Wellcome Inc., Research Triangle Park, North Carolina U.S.A.
    Search for articles by this author
      This paper is only available as a PDF. To read, Please Download here.


      The Modernization Act of 1997 is the result of a partnership between the US Food and Drug Administration (FDA) and the pharmaceutical industry. Highlights of the Act, including agreements on user fees, timely review, pediatric studies, and national registry of clinical trials, are presented. Although progress has been made in each of these areas, this paper concerns the profound impact of combinatorial chemistry, genetic research, and pharmacoeconomics on the FDA, the industry, and the drug development process.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect